{"id":9653,"date":"2016-03-28T16:25:40","date_gmt":"2016-03-28T15:25:40","guid":{"rendered":"https:\/\/mileon.wordpress.com\/?p=9653"},"modified":"2016-03-28T16:25:40","modified_gmt":"2016-03-28T15:25:40","slug":"sesion-de-residentes-antiagregacion-en-neurologia","status":"publish","type":"post","link":"https:\/\/www.icscyl.com\/mileon\/residentes\/2016-03-28\/sesion-de-residentes-antiagregacion-en-neurologia\/","title":{"rendered":"Sesi\u00f3n de residentes: antiagregaci\u00f3n en Neurolog\u00eda."},"content":{"rendered":"<p style=\"text-align:justify;\"><a href=\"https:\/\/mileon.wordpress.com\/2016\/03\/28\/sesion-de-residentes-antiagregacion-en-neurologia\/imagen-300\/#main\" rel=\"attachment wp-att-9654\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright  wp-image-9654\" src=\"https:\/\/mileon.files.wordpress.com\/2016\/03\/imagen6.jpg\" alt=\"imagen\" width=\"141\" height=\"92\" \/><\/a>El 28 de marzo de 2016 el Dr. Gerard Sancho Pascual (R2 MI) coment\u00f3 los aspectos m\u00e1s relevantes sobre el uso de los anti-agregantes en la enfermedad cerebrovascular tanto en las fases agudas como en prevenci\u00f3n secundaria.<br \/>\nRecoge las indicaciones, f\u00e1rmacos y dosis a utilizar. Nos recuerda la poca utilidad de la doble anti-agregaci\u00f3n y cuando hay que anti-coagular.<br \/>\nSu presentaci\u00f3n se puede ver en el siguiente <strong><a href=\"https:\/\/drive.google.com\/file\/d\/0BxXYCqMXR4ZaVkh0SEVkazBNb0E\/view?usp=sharing\">enlace.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El 28 de marzo de 2016 el Dr. Gerard Sancho Pascual (R2 MI) coment\u00f3 los aspectos m\u00e1s relevantes sobre el uso de los anti-agregantes en la enfermedad cerebrovascular tanto en las fases agudas como en prevenci\u00f3n secundaria. Recoge las indicaciones, f\u00e1rmacos y dosis a utilizar. Nos recuerda la poca utilidad de la doble anti-agregaci\u00f3n y [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[721],"tags":[],"class_list":["post-9653","post","type-post","status-publish","format-standard","hentry","category-residentes"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/9653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=9653"}],"version-history":[{"count":0,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/9653\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=9653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=9653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=9653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}